The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP)

British Journal of Pharmacology

Volumn 171, Issue 12, 2014, Pages 3051-3064

  Pergola, Carlo ^a   Gerstmeier, J ^a   Monch B ^a   Caliskan B ^b   Luderer, S ^c   Weinigel, C ^d   Barz, D ^d   Maczewsky, J ^a   Pace, S ^a   Rossi, Antonietta ^e   Sautebin, L ^e   Banoglu, E ^b   Werz, O ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b GAZI UNIVERSITY   (Turkey)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

5 lipoxygenase; 5 lipoxygenase activating protein; benzimidazole; inflammation; leukotriene

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BENZIMIDAZOLE DERIVATIVE; BRP 7; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 3A4; LEUKOTRIENE; POTASSIUM CHANNEL HERG; PROSTAGLANDIN E2; PROSTAGLANDIN E2 SYNTHASE 1; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; 1-(2-CHLOROBENZYL)-2-(1-(4-ISOBUTYLPHENYL)ETHYL)-1H-BENZIMIDAZOLE; ALOX5 PROTEIN, HUMAN; ALOX5AP PROTEIN, HUMAN; ALOX5AP PROTEIN, MOUSE; ALOX5AP PROTEIN, RAT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; CARRAGEENAN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZYMOSAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOSYNTHESIS; CARRAGEENAN-INDUCED PLEURISY; CELL FREE SYSTEM; CELL VIABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; ZYMOSAN-INDUCED PERITONITIS; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PERITONITIS; PLEURISY; WISTAR RAT;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; 5-LIPOXYGENASE-ACTIVATING PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; BENZIMIDAZOLES; CARRAGEENAN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; MICE; MONOCYTES; NEUTROPHILS; PERITONITIS; PLEURISY; RATS, WISTAR; ZYMOSAN;

EID: 84901407496     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12625     Document Type: Article

References (48)

1. Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ, (1993). 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 215: 105-111.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Back M, (2009). Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 15: 3116-3132.
4. Bain G, King CD, Schaab K, Rewolinski M, Norris V, Ambery C, et al. (2013). Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharmacol 75: 779-790.
5. Bair AM, Turman MV, Vaine CA, Panettieri RA Jr, Soberman RJ, (2012). The nuclear membrane leukotriene synthetic complex is a signal integrator and transducer. Mol Biol Cell 23: 4456-4464.
6. Banoglu E, Caliskan B, Luderer S, Eren G, Ozkan Y, Altenhofen W, et al. (2012). Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase- activating protein (FLAP). Bioorg Med Chem 20: 3728-3741.
7. Byrum RS, Goulet JL, Griffiths RJ, Koller BH, (1997). Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 185: 1065-1075.
8. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. (1991). 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256: 929-937.
9. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, et al. (2003). Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 170: 4738-4744.
10. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH, (2008). What's all the FLAP about? 5-Lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 29: 72-78.
11. Ferguson AD, (2012). Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein. Methods Mol Biol 841: 267-290.
12. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, et al. (2007). Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317 (5837): 510-512.
13. Fischer L, Steinhilber D, Werz O, (2004). Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 142: 861-868.
14. 2+mobilisation in polymorphonuclear leukocytes involving Src family kinases. Biochim Biophys Acta 1736: 109-119.
15. Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y, et al. (2007). The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 152: 471-480.
16. Follows RM, Snowise NG, Ho SY, Ambery CL, Smart K, McQuade BA, (2013). Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir Res 14: 54.
17. Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Muller-Peddinghaus R, (1993). Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Biochem Pharmacol 45: 101-111.
18. Hofmann B, Steinhilber D, (2013). 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012). Expert Opin Ther Pat 23: 895-909.
19. Hutchinson JH, Li Y, Arruda JM, Baccei C, Bain G, Chapman C, et al. (2009). 5-Lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl] -5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103). J Med Chem 52: 5803-5815.
20. Kent SE, Boyce M, Diamant Z, Singh D, O'Connor BJ, Saggu PS, et al. (2013). The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 43: 177-186.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
22. Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S, Albrecht W, et al. (2008). Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326: 975-982.
23. Koeberle A, Siemoneit U, Northoff H, Hofmann B, Schneider G, Werz O, (2009). MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation. Eur J Pharmacol 608: 84-90.
24. Kolaczkowska E, Shahzidi S, Seljelid R, van Rooijen N, Plytycz B, (2002). Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes. Inflammation 26: 61-71.
25. Laufer S, Tries S, Augustin J, Dannhardt G, (1994a). Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung 44: 629-636.
26. Laufer SA, Augustin J, Dannhardt G, Kiefer W, (1994b). (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 37: 1894-1897.
27. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Leveille C, Mancini JA, et al. (1990). Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343 (6255): 278-281.
29. Pergola C, Werz O, (2010). 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 20: 355-375.
30. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, et al. (2008). ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A 105: 19881-19886.
31. Pergola C, Rogge A, Dodt G, Northoff H, Weinigel C, Barz D, et al. (2011). Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. FASEB J 25: 3377-3387.
32. Pergola C, Jazzar B, Rossi A, Northoff H, Hamburger M, Sautebin L, et al. (2012). On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo. Br J Pharmacol 165: 765-776.
33. Peters-Golden M, Henderson WR Jr, (2007). Leukotrienes. N Engl J Med 357: 1841-1854.
34. Radmark O, Werz O, Steinhilber D, Samuelsson B, (2007). 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32: 332-341.
35. Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al. (2009). Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 68: 938-947.
36. Riccioni G, Back M, (2012). Leukotrienes as modifiers of preclinical atherosclerosis? ScientificWorldJournal 2012: 490968.
37. Sampson AP, (2009). FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs 10: 1163-1172.
38. Sardella R, Levent S, Ianni F, Caliskan B, Gerstmeier J, Pergola C, et al. (2013). Chromatographic separation and biological evaluation of benzimidazole derivative enantiomers as inhibitors of leukotriene biosynthesis. J Pharm Biomed Anal 89C: 88-92.
39. Snowise NG, Clements D, Ho SY, Follows RM, (2013). Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma. Curr Med Res Opin 29: 1663-1674.
40. Stock NS, Bain G, Zunic J, Li Y, Ziff J, Roppe J, et al. (2011). 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem 54: 8013-8029.
41. Surette ME, Palmantier R, Gosselin J, Borgeat P, (1993). Lipopolysaccharides prime whole human blood and isolated neutrophils for the increased synthesis of 5-lipoxygenase products by enhancing arachidonic acid availability: involvement of the CD14 antigen. J Exp Med 178: 1347-1355.
42. Tretiakova I, Blaesius D, Maxia L, Wesselborg S, Schulze-Osthoff K, Cinatl J Jr, et al. (2008). Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9. Apoptosis 13: 119-131.
43. Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, et al. (1997). Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 390 (6660): 618-622.
44. Werz O, Szellas D, Henseler M, Steinhilber D, (1998). Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 54: 445-451.
45. Werz O, Klemm J, Samuelsson B, Radmark O, (2001). Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 97: 2487-2495.
46. Werz O, Burkert E, Samuelsson B, Radmark O, Steinhilber D, (2002). Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99: 1044-1052.
47. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, et al. (2008). Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol 154: 1446-1456.
48. Zarini S, Gijon MA, Folco G, Murphy RC, (2006). Effect of arachidonic acid reacylation on leukotriene biosynthesis in human neutrophils stimulated with granulocyte-macrophage colony-stimulating factor and formyl-methionyl- leucyl-phenylalanine. J Biol Chem 281: 10134-10142.